| | Staff Scientists and Clinicians
| Douglas W. Jones, Ph.D. |
 |
|
Dr. Jones is a Research Physicist with the Clinical Brain Disorders Branch of the Intramural Research
Program, National Institute of Mental Health, National Institutes of Health in Bethesda, Maryland. He
received a Bachelor of Science degree in physics from Stanford University, a Master of Science degree
in physics from the University of British Columbia and a Doctor of Philosophy degree in physics, with a
minor in optical sciences, from the University of Arizona. Prior to his appointment with the NIMH, he
worked as a university professor for a year and had a three-year National Research Council Post-doctoral
Research Fellowship at the National Institute of Standards and Technology (formerly the National Bureau
of Standards). He joined the NIMH in 1984 as a technical expert for the Laboratory of Psychology and
Psychopathology. In 1986 he was reassigned to the Clinical Brain Disorders Branch at its inception so
that he could apply his expertise in physics, image processing, data analysis, computer programming
and electronic design to the Single Photon Emission Computed Tomography (SPECT) Laboratory of that
branch. Since 1998, Dr. Jones has been the Facility Head of the NIMH SPECT Laboratory of the Clinical
Brain Disorders Branch overseeing its day-to-day operation as it pursues the goals set forth by the
Branch Chief. |
| Research Interests |
Dr. Jones' research endeavors at the NIMH have focused primarily on in vivo molecular neuroimaging studies in human and nonhuman primates of proteins directly involved in neurotransmission. In human patients, the NIMH SPECT Laboratory has studied a number of neuropsychiatric disorders; these include schizophrenia, Alzheimer's disease, Parkinson's disease, Tourette's syndrome and alcoholism. The interactions of psychopharmacological agents with neurotransmitter receptors and transporters have also been examined in vivo using these techniques. Similarly, genetic interactions have been explored. In addition to SPECT imaging, Dr. Jones has extensive experience in the analysis of MRI data including structural MRI morphometry and, more recently, functional MRI (fMRI).
He has recently begun collaborating with Dr. King Li, associate director of the Radiology and Imaging
Sciences Department and director of Diagnostic Radiology, and Michael Green of the NIH CC PET
Department in the development and implementation of a novel SPECT imaging device for small animal
imaging. He also plans to continue work on the analysis of event related fMRI, and he hopes one day to
set up a Near-Infrared Spectroscopy (NIRS) imaging system to measure quantitatively cortical blood flow
in real-time. |
| Representative Selected Recent Publications: |
- Raedler TJ, Knable MB, Jones DW, Urbina RA, Gorey JG, Lee KS, Egan MF, Coppola R, Weinberger DR: In vivo determination of muscarinic acetylcholine receptor availability in schizophrenia. Am J Psychiatry (in press), 2003.
- Winterer G, Adams CM, Jones DW, Knutson B:: Volition to action - An event-related fMRI-study. Neuroimage, 17:851-858, 2002.
- Raedler TJ, Knable MB, Jones DW, Lafargue T, Urbina RA, Egan MF, Pickar D, Weinberger DR:: In vivo olanzapine occupancy of muscarinic acetylcholine receptors in patients with schizophrenia. Neuropsychopharmacology, 23:56-68, 2000.
- Heinz A, Jones DW, Mazzanti C, Goldman D, Ragan P, Hommer D, Linnoila M, Weinberger DR: A relationship between serotonin transporter genotype and in vivo protein expression and alcohol neurotoxicity. Biol Psychiatry, 47:643-649, 2000.
- Heinz A, Goldman D, Jones DW, Palmour R, Hommer D, Gorey JG, Lee KS, Linnoila M, Weinberger DR:: Genotype influences in vivo dopamine transporter availability in human striatum. Neuropsychopharmacology 22:133-139, 2000.
|
|
|
|
|
